Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Christopher P. Venner, MD, Nizar J Bahlis, MD, Paola Neri, MD PhD, Irwindeep Sandhu, MD, Peter Duggan, MD, Andrew Belch, MD, Joanne D Hewitt, RN, BSN, NP, Linda M. Pilarski, PhD, Tatiana Nikitina, Victor H Jimenez-Zepeda, MD

Blood (2015) 126 (23): 4261.

https://doi.org/10.1182/blood.V126.23.4261.4261

Published: 2015

Journal Articles

Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Marcia Culham, RN, BSN, NP, Joanne Luider, Fariborz Rashid-Kolvear, PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 3189.

https://doi.org/10.1182/blood.V126.23.3189.3189

Published: 2015

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Victor H Jimenez-Zepeda, MD, Christopher P. Venner, MD, Andrew Belch, Irwindeep Sandhu, MD, Tatiana Nikitina, Joanne D Hewitt, RN, BSN, NP, Peter Duggan, MD, Paola Neri, MD PhD, Fariborz Rashid-Kolvear, PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 1845.

https://doi.org/10.1182/blood.V126.23.1845.1845

Published: 2015

Journal Articles

Bortezomib-Containing Regimens (BCR) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 1846.

https://doi.org/10.1182/blood.V126.23.1846.1846

Published: 2015

Journal Articles

Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed By ASCT with HDM or Bor-HDM Conditioning Regimens: A Single Center Experience

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Joanne Luider, Nizar J Bahlis, MD

Blood (2015) 126 (23): 5492.

https://doi.org/10.1182/blood.V126.23.5492.5492

Published: 2015

Journal Articles

Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

Blood (2015) 126 (23): 5384.

https://doi.org/10.1182/blood.V126.23.5384.5384

Published: 2015

Journal Articles

Bortezomib Containing Regimens Are Highly Effective for Systemic AL Amyloidosis: Experience from a Single Center

Victor H Jimenez Zepeda, MD, Peter Duggan, MD, Paola E. Neri, MD PhD, Nizar J Bahlis, MD

Blood (2014) 124 (21): 4743.

https://doi.org/10.1182/blood.V124.21.4743.4743

Published: 2014

Journal Articles

Pomalidomide and Dexamethasone Is an Effective Regimen for Advanced-Stage Relapsed/Refractory Multiple Myeloma: Experience of a Single Center

Victor H Jimenez Zepeda, MD, Peter Duggan, MD, Paola E. Neri, MD PhD, Nizar J Bahlis, MD

Blood (2014) 124 (21): 5747.

https://doi.org/10.1182/blood.V124.21.5747.5747

Published: 2014

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Is a Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients

Victor H Jimenez Zepeda, MD, Peter Duggan, MD, Paola E. Neri, MD PhD, Nizar J Bahlis, MD

Blood (2014) 124 (21): 5751.

https://doi.org/10.1182/blood.V124.21.5751.5751

Published: 2014

Journal Articles

Cereblon (CRBN) Splice Isoform Lacking Exon 10 Attenuates Lenalidomide-Mediated Degradation of Aiolos and Is Upregulated in Immunomodulatory Drugs (IMiDs) Resistant Myeloma (MM) Patients

Ranjan Maity, PhD, Paola E. Neri, MD PhD, Ines Tagoug, PhD, Li Ren, PhD, Jiri Slaby, MD, Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Justin Simms, Nizar J Bahlis, MD

Blood (2014) 124 (21): 639.

https://doi.org/10.1182/blood.V124.21.639.639

Published: 2014

Journal Articles

Bortezomib and Melphalan (Bor/MEL) Conditioning for Patients with Multiple Myeloma Undergoing Single Autologous Stem Cell Transplantation

Victor H Jimenez Zepeda, MD, Peter Duggan, MD, Paola E. Neri, MD PhD, Nizar J Bahlis, MD

Blood (2014) 124 (21): 1202.

https://doi.org/10.1182/blood.V124.21.1202.1202

Published: 2014

Journal Articles

Transcriptome Profiling of Lenalidomide Treated Myeloma Patients Identifies an Interferon Signature Gene Response and a Novel IRF4/MYC Independent Mechanism of Resistance

Paola E. Neri, MD PhD, Ines Tagoug, PhD, Li Ren, PhD, Ranjan Maity, PhD, Justin Simms, Peter Duggan, MD, Victor H Jimenez-Zepeda, MD, Jiri Slaby, MD, Howie Wu, Jackie Babich, Nizar J Bahlis, MD

Blood (2014) 124 (21): 170.

https://doi.org/10.1182/blood.V124.21.170.170

Published: 2014

Journal Articles

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis

Donna E. Reece, MD, Madeline Phillips, BAS, Beryl Chung, Christine I. Chen, MD, Esther Masih-Khan, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 3231.

https://doi.org/10.1182/blood.V122.21.3231.3231

Published: 2013

Journal Articles

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

Victor H Jimenez Zepeda, MD, Suzanne Trudel, MD, MSC, FRCPC, Donna E. Reece, MD, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Norman Franke, MD, Andrew Winter, Sr., RN, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 3396.

https://doi.org/10.1182/blood.V122.21.3396.3396

Published: 2013

Journal Articles

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Sophia Farooki, MD, FRCPC, Manjula Maganti, Donna E Reece, MD, FRCPC, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5315.

https://doi.org/10.1182/blood.V122.21.5315.5315

Published: 2013

Journal Articles

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Victor H Jimenez Zepeda, MD, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP, FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5398.

https://doi.org/10.1182/blood.V122.21.5398.5398

Published: 2013

Journal Articles

Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)

Donna E. Reece, MD, Madeline Phillips, BAS, Christine I. Chen, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Suzanne Trudel, MD, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5378.

https://doi.org/10.1182/blood.V122.21.5378.5378

Published: 2013

Journal Articles

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

Victor H Jimenez-Zepeda, MD, PD, Donna Reece, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD, PhD, FRACP, FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 4064.

https://doi.org/10.1182/blood.V120.21.4064.4064

Published: 2012

Journal Articles

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Klaus Martin Kortuem, MD, Steven R Schuster, MD, Meaghan L. Khan, MD, Kaitlyn E. Zidich, Victor H Jimenez-Zepeda, MD, Rafael Fonseca, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4034.

https://doi.org/10.1182/blood.V120.21.4034.4034

Published: 2012

Journal Articles

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Danielle C Croucher, Victor H Jimenez-Zepeda, MD, PD, Zhi Hua Li, Ellen Wei, Brent DG Page, James Turkson, Patrick T Gunning, Suzanne Trudel, MD, MSC, FRCPC

Blood (2011) 118 (21): 5101.

https://doi.org/10.1182/blood.V118.21.5101.5101

Published: 2011

NARROW

In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort

Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Lenalidomide and Dexamethasone (LD) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Bortezomib-Containing Regimens (BCR) for the Treatment of Non-Transplant Eligible Multiple Myeloma

Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed By ASCT with HDM or Bor-HDM Conditioning Regimens: A Single Center Experience

Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

Bortezomib Containing Regimens Are Highly Effective for Systemic AL Amyloidosis: Experience from a Single Center

Pomalidomide and Dexamethasone Is an Effective Regimen for Advanced-Stage Relapsed/Refractory Multiple Myeloma: Experience of a Single Center

Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Is a Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients

Cereblon (CRBN) Splice Isoform Lacking Exon 10 Attenuates Lenalidomide-Mediated Degradation of Aiolos and Is Upregulated in Immunomodulatory Drugs (IMiDs) Resistant Myeloma (MM) Patients

Bortezomib and Melphalan (Bor/MEL) Conditioning for Patients with Multiple Myeloma Undergoing Single Autologous Stem Cell Transplantation

Transcriptome Profiling of Lenalidomide Treated Myeloma Patients Identifies an Interferon Signature Gene Response and a Novel IRF4/MYC Independent Mechanism of Resistance

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL)

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

The Potent STAT3/5 Inhibitor, BP-1-102 Demonstrates Significant Anti-Tumor Activity Against Waldenström Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only